Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer
- 1 March 2007
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 104 (3) , 612-616
- https://doi.org/10.1016/j.ygyno.2006.09.023
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patientsAnnals of Oncology, 2006
- A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinomaGynecologic Oncology, 2005
- The role of surgery in recurrent ovarian cancerInternational Journal of Gynecologic Cancer, 2005
- 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)Annals of Oncology, 2005
- Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancerInternational Journal of Gynecologic Cancer, 2005
- Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancerBreast Cancer Research and Treatment, 2005
- Renal cell carcinoma: review of novel single-agent therapeutics and combination regimensAnnals of Oncology, 2005
- Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian CarcinomaJNCI Journal of the National Cancer Institute, 2004
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989